首页> 美国卫生研究院文献>The Journal of International Medical Research >Simultaneous ABO-incompatible living-donor liver transplantation andsplenectomy without plasma exchange in China: Two case reports
【2h】

Simultaneous ABO-incompatible living-donor liver transplantation andsplenectomy without plasma exchange in China: Two case reports

机译:同时进行ABO不相容的活体供肝移植和中国没有血浆置换的脾切除术:两例报道

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ABO-incompatible (ABO-i) living-donor liver transplantation (LDLT) is performed if an ABO-compatible graft cannot be obtained. However, a perfect desensitization protocol has not been established worldwide, especially for simultaneous ABO-i LDLT and splenectomy. We herein report two cases of ABO-i LDLT. To the best of our knowledge, this is the first case report of ABO-i LDLT in an adult patient in China. Splenectomy and T-cell-targeted immunosuppression (basiliximab) was used to overcome the blood group barrier in these recipients. The patients had good graft function without signs of antibody-mediated rejection throughout the 12-month follow-up. Thus, ABO-i LDLT with splenectomy is undoubtedly life-saving when an ABO-compatible graft cannot be obtained for patients in critical condition.
机译:如果无法获得与ABO兼容的移植物,则进行ABO不兼容(ABO-i)的活体供体肝移植(LDLT)。但是,尚未在世界范围内建立完善的脱敏方案,特别是对于同时进行的ABO-i LDLT和脾切除术。我们在此报告了两种ABO-i LDLT病例。据我们所知,这是ABO-i LDLT在中国成年患者中的首例病例报告。脾切除术和靶向T细胞的免疫抑制(basiliximab)用于克服这些接受者的血型障碍。在整个12个月的随访中,患者的移植物功能良好,没有抗体介导的排斥反应的迹象。因此,当危重患者无法获得与ABO兼容的移植物时,ABO-i LDLT脾切除术无疑可以挽救生命。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号